arrow
S

Stefan Fröhling

german cancer research center
H指数:80
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-specific super-enhancer drives overexpression of EVI1/MECOM in ovarian cancer

肿瘤特异性超级增强子驱动卵巢癌中<em>EVI1/MECOM</em>的过表达

2026-10-120
OAAI
The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial

学校青少年吸烟预防的“吸烟脸”海报宣传活动:一项集群随机对照试验

2026-06-190
OA
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor

多层分子分析为硬化性小圆细胞肿瘤的诊断和靶向治疗提供信息

2026-04-090
OA
The Knowledge Connector decision support system for multiomics-based precision oncology

基于多组学的精准肿瘤学知识连接器决策支持系统

2026-01-190
OAAI
Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

开发基于证据、具有成本效益的P4癌症医学,以推动在预防、治疗、患者护理方面的创新,并减少医疗不平等。

2025-12-150
OAAI
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials

将无进展生存比作为精准肿瘤学临床试验的主要终点进行基准测试

2025-12-150
OAAI
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

在转移性乳腺癌中实施精准肿瘤学:全面基因组分析的临床影响——CATCH研究经验

2025-10-310
OAAI
Germany’s national genomDE strategy

德国国家基因组策略

2025-10-150
PRE
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/ 5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial

PAMSARC(在表达SSTR2/3/5的滑膜肉瘤和弥漫性小圆细胞瘤中使用帕西瑞肽作为每月深部肌肉注射的维持治疗)多中心II期试验的原理与设计

2025-09-010
OAAI
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

双等位基因抗原逃逸是抗CD38抗体在多发性骨髓瘤中的一种耐药机制。

Blood
IF23.1
2025-06-160
PRE
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (vol 149, pg 913, 2022)

德国卓越中心在COVID-19大流行第一年中的癌症护理(vol 149, pg 913, 2022)

2025-01-180
OA
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma

选择性靶向TBXT的DARPins识别了软骨肉瘤中的调控网络和治疗易感性

2025-01-010
OA
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma
2024-08-202
OAAI